GlaxoSmithKline agreed to pay more than $41 million in restitution to end claims by more than 40 state Medicaid programs that it inflated the prices of drugs used by cancer patients and others. With some state lawsuits still pending, the company expects eventually to pay a total of $70 million, a GlaxoSmithKline spokeswoman said. The company did not admit wrongdoing. GlaxoSmithKline allegedly inflated average wholesale prices for drugs that help patients overcome nausea and other effects of chemotherapy.
Drugmaker settles suits over average wholesale price
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.